Compass CTX-471 (Advanced or Metastatic Cancer) - Clinical Trial
What is the Purpose of this Study?
Treatment
We are doing this study to find out if an investigational drug, CTX-471, is safe and effective against your cancer.
What is the Condition Being Studied?
Objective
Metastatic or locally advanced cancer that did not respond to prior treatment with a PD-1 or PD-L1 inhibitor
Who Can Participate in the Study?
Key Eligibility
Adults who have metastatic or locally advanced cancer who:
- Did not respond to prior treatment with a PD-1 or PD-L1 inhibitor
- Have not had other systemic anticancer therapy
Age Group
Adults
What is Involved?
Description
If you choose to join this study, you will:
- Have an infusion of the study drug (CTX-471) once every 2 weeks
- Have a tumor biopsy
- Have an eye exam
- Have physical exams, blood and urine tests
- Have imaging scans (CT and/or MRI)
- Have tests of your heart (ECG)
Study Details
Full Title
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination with Pembrolizumab in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00103011
NCT:
NCT03881488
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment